| Abstrakt: |
Background/Aims Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer-related mortality in the Unites States. Although surgical resection provides the only change for a cure, there is a high rate of disease recurrence. Until now, several studies revealed the benefit of adjuvant treatment after surgical resection. The purpose of this study was to compare disease-free survival (DFS) and overall survival (OS) between patients with adjuvant therapy and surgery alone according to 8th American Joint Committee on Cancer (AJCC) TNM staging system. Methods We reviewed medical record for patients with PDAC who underwent curative surgical resection between 2011 and 2018. Excluding R1 resection, postoperative death, and recurrence within 3 months after surgery, DFS and OS were compared between patients with adjuvant therapy and those with surgery alone. Results A total of 140 patients (median age, 68 years; range, 42 to 85 years; male:female= 71:69) were eligible; while 58 patients (41.4%) were treated with chemotherapy or chemoradiation, 82 (58.6%) were treated with surgery alone. There were no differences in DFS and OS between patients with adjuvant treatment and those with surgery alone (14.7±1.2 months vs 9.7±1.0 months, log-rank=0.469; 27.5±16.6 months vs 18.3±1.8 months, log-rank=0.055). Among patients with stage III, adjuvant therapy was associated with higher DSF and OS compared with surgery alone (14.6±3.4 months vs 7.9±0.8 months, log-rank=0.23; 47.7±16.7 months vs 11.0±1.7 months, log-rank=0.001). Conclusions Our study showed the benefit of adjuvant therapy in patients with surgically resected stage III PDAC according to 8th AJCC TNM stage system. Further prospective study including many cases and variable manage options is required to validate our results. [ABSTRACT FROM AUTHOR] |
